Acebutolol
Acebutolol may decrease the bronchodilatory activities of Salbutamol.
Acemetacin
The therapeutic efficacy of Acemetacin can be decreased when used in combination with Salbutamol.
Alfuzosin
Alfuzosin may decrease the vasoconstricting activities of Salbutamol.
Advertisement
Alprenolol
Alprenolol may decrease the bronchodilatory activities of Salbutamol.
Amineptin
The risk or severity of adverse effects can be increased when Amineptine is combined with Salbutamol.
Amiodarone
Salbutamol may increase the QTc-prolonging activities of Amiodarone.
Advertisement
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Salbutamol.
Amoxapine
The therapeutic efficacy of Salbutamol can be decreased when used in combination with Amoxapine.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Salbutamol.
Advertisement
Anagrelide
Salbutamol may increase the QTc-prolonging activities of Anagrelide.
Arsenic Trioxide
Salbutamol may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Salbutamol may increase the QTc-prolonging activities of Artemether.
Asenapine
Salbutamol may increase the QTc-prolonging activities of Asenapine.
Atenolol
Atenolol may decrease the bronchodilatory activities of Salbutamol.
Atomoxetine
Atomoxetine may increase the tachycardic activities of Salbutamol.
Atorvastatin
The risk or severity of adverse effects can be increased when Salbutamol is combined with Atorvastatin.
Atosiban
The risk or severity of adverse effects can be increased when Salbutamol is combined with Atosiban.
Azithromycin
Salbutamol may increase the QTc-prolonging activities of Azithromycin.
Azosemide
Salbutamol may increase the hypokalemic activities of Azosemide.
Bedaquiline
Salbutamol may increase the QTc-prolonging activities of Bedaquiline.
Bendroflumethiazide
Salbutamol may increase the hypokalemic activities of Bendroflumethiazide.
Benzylpenicilloyl polylysine
Salbutamol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BETAHISTINE
The therapeutic efficacy of Salbutamol can be decreased when used in combination with Betahistine.
Betaxolol
Betaxolol may decrease the bronchodilatory activities of Salbutamol.
Bisoprolol
Bisoprolol may decrease the bronchodilatory activities of Salbutamol.
Bopindolol
Bopindolol may decrease the bronchodilatory activities of Salbutamol.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Salbutamol.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Salbutamol.
Bromocriptine
Bromocriptine may increase the hypertensive and vasoconstricting activities of Salbutamol.
Bumetanide
Salbutamol may increase the hypokalemic activities of Bumetanide.
Bunazosin
Bunazosin may decrease the vasoconstricting activities of Salbutamol.
Bupranolol
Bupranolol may decrease the bronchodilatory activities of Salbutamol.
Cabergoline
Cabergoline may increase the hypertensive and vasoconstricting activities of Salbutamol.
Calcium Carbimide
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Salbutamol.
Carteolol
Carteolol may decrease the bronchodilatory activities of Salbutamol.
Carvedilol
Carvedilol may decrease the vasoconstricting activities of Salbutamol.
Celiprolol
Celiprolol may decrease the bronchodilatory activities of Salbutamol.
Ceritinib
Salbutamol may increase the QTc-prolonging activities of Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Salbutamol.
Chloroquine
Salbutamol may increase the QTc-prolonging activities of Chloroquine.
Chlorothiazide
Salbutamol may increase the hypokalemic activities of Chlorothiazide.
Chlorpromazine
Salbutamol may increase the QTc-prolonging activities of Chlorpromazine.
Chlorthalidone
Salbutamol may increase the hypokalemic activities of Chlorthalidone.
Ciprofloxacin
Salbutamol may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Salbutamol may increase the QTc-prolonging activities of Cisapride.
Citalopram
Salbutamol may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
Salbutamol may increase the QTc-prolonging activities of Clarithromycin.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Salbutamol.
Clozapine
Salbutamol may increase the QTc-prolonging activities of Clozapine.
Crizotinib
Salbutamol may increase the QTc-prolonging activities of Crizotinib.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salbutamol.
Cyclopenthiazide
Salbutamol may increase the hypokalemic activities of Cyclopenthiazide.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Salbutamol.
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Salbutamol.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Salbutamol.
Disopyramide
Salbutamol may increase the QTc-prolonging activities of Disopyramide.
Dofetilide
Salbutamol may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Salbutamol may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Salbutamol may increase the QTc-prolonging activities of Domperidone.
Dothiepin
The risk or severity of adverse effects can be increased when Dosulepin is combined with Salbutamol.
Doxazosin
Doxazosin may decrease the vasoconstricting activities of Salbutamol.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Salbutamol.
Dronedarone
Salbutamol may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Salbutamol may increase the QTc-prolonging activities of Droperidol.
Duloxetine
Duloxetine may increase the tachycardic activities of Salbutamol.
Eliglustat
Salbutamol may increase the QTc-prolonging activities of Eliglustat.
ergoloid mesylates, USP
Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Salbutamol.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Salbutamol.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Salbutamol.
Erythromycin
Salbutamol may increase the QTc-prolonging activities of Erythromycin.
Escitalopram
Salbutamol may increase the QTc-prolonging activities of Escitalopram.
Esmolol
Esmolol may decrease the bronchodilatory activities of Salbutamol.
Ethacrynate
Salbutamol may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Salbutamol may increase the hypokalemic activities of Etacrynic acid.
Flecainide
Salbutamol may increase the QTc-prolonging activities of Flecainide.
Fluoxetine
Salbutamol may increase the QTc-prolonging activities of Fluoxetine.
Flupenthixol
Salbutamol may increase the QTc-prolonging activities of Flupentixol.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Salbutamol.
Furazolidone
The risk or severity of adverse effects can be increased when Furazolidone is combined with Salbutamol.
Furosemide
Salbutamol may increase the hypokalemic activities of Furosemide.
Gadobenate
Salbutamol may increase the QTc-prolonging activities of Gadobenic acid.
Gemifloxacin
Salbutamol may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Salbutamol may increase the QTc-prolonging activities of Gemifloxacin.
Goserelin
Salbutamol may increase the QTc-prolonging activities of Goserelin.
Granisetron
Salbutamol may increase the QTc-prolonging activities of Granisetron.
Haloperidol
Salbutamol may increase the QTc-prolonging activities of Haloperidol.
Hydrochlorothiazide
Salbutamol may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Salbutamol may increase the hypokalemic activities of Hydroflumethiazide.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Salbutamol.
Ibutilide
Salbutamol may increase the QTc-prolonging activities of Ibutilide.
Iloperidone
Salbutamol may increase the QTc-prolonging activities of Iloperidone.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Salbutamol.
Indapamide
Salbutamol may increase the hypokalemic activities of Indapamide.
Indoramin
Indoramin may decrease the vasoconstricting activities of Salbutamol.
Iproniazid
The risk or severity of adverse effects can be increased when Iproniazid is combined with Salbutamol.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salbutamol.
Labetalol
Labetalol may decrease the vasoconstricting activities of Salbutamol.
Lacidipine
Salbutamol may increase the hypotensive activities of Lacidipine.
Lenvatinib
Salbutamol may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Salbutamol may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Salbutamol may increase the QTc-prolonging activities of Leuprolide.
Levofloxacin
Salbutamol may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Salbutamol may increase the QTc-prolonging activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Salbutamol.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Salbutamol.
Lopinavir
Salbutamol may increase the QTc-prolonging activities of Lopinavir.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Salbutamol.
Lumefantrine
Salbutamol may increase the QTc-prolonging activities of Lumefantrine.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Salbutamol.
Methadone
Salbutamol may increase the QTc-prolonging activities of Methadone.
Methyclothiazide
Salbutamol may increase the hypokalemic activities of Methyclothiazide.
Methylene blue
The risk or severity of adverse effects can be increased when Methylene blue is combined with Salbutamol.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Salbutamol.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Salbutamol.
Metolazone
Salbutamol may increase the hypokalemic activities of Metolazone.
Metoprolol
Metoprolol may decrease the bronchodilatory activities of Salbutamol.
Mifepristone
Mifepristone may increase the QTc-prolonging activities of Salbutamol.
Milnacipran
Milnacipran may increase the tachycardic activities of Salbutamol.
Minaprine
The risk or severity of adverse effects can be increased when Minaprine is combined with Salbutamol.
Mirtazapine
The risk or severity of adverse effects can be increased when Mirtazapine is combined with Salbutamol.
Moclobemide
The risk or severity of adverse effects can be increased when Moclobemide is combined with Salbutamol.
Moxifloxacin
Salbutamol may increase the QTc-prolonging activities of Moxifloxacin.
Nebivolol
Nebivolol may decrease the bronchodilatory activities of Salbutamol.
Nialamide
The risk or severity of adverse effects can be increased when Nialamide is combined with Salbutamol.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Salbutamol.
Nilotinib
Salbutamol may increase the QTc-prolonging activities of Nilotinib.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Salbutamol.
Ofloxacin
Salbutamol may increase the QTc-prolonging activities of Ofloxacin.
Ondansetron
Salbutamol may increase the QTc-prolonging activities of Ondansetron.
Opipramol
The risk or severity of adverse effects can be increased when Opipramol is combined with Salbutamol.
Oxprenolol
Oxprenolol may decrease the bronchodilatory activities of Salbutamol.
Paliperidone
Salbutamol may increase the QTc-prolonging activities of Paliperidone.
Panobinostat
Salbutamol may increase the QTc-prolonging activities of Panobinostat.
Pargyline
The risk or severity of adverse effects can be increased when Pargyline is combined with Salbutamol.
Pazopanib
Salbutamol may increase the QTc-prolonging activities of Pazopanib.
Pentamidine
Salbutamol may increase the QTc-prolonging activities of Pentamidine.
Perflutren
Salbutamol may increase the QTc-prolonging activities of Perflutren.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Salbutamol.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Salbutamol.
Pimozide
Salbutamol may increase the QTc-prolonging activities of Pimozide.
Piretanide
Salbutamol may increase the hypokalemic activities of Piretanide.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Salbutamol.
Polythiazide
Salbutamol may increase the hypokalemic activities of Polythiazide.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Salbutamol.
Prazosin
Prazosin may decrease the vasoconstricting activities of Salbutamol.
Primaquine
Salbutamol may increase the QTc-prolonging activities of Primaquine.
Procainamide
Salbutamol may increase the QTc-prolonging activities of Procainamide.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Salbutamol.
Promazine
Salbutamol may increase the QTc-prolonging activities of Promazine.
Propafenone
Salbutamol may increase the QTc-prolonging activities of Propafenone.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Salbutamol.
Quetiapine
Salbutamol may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Salbutamol may increase the QTc-prolonging activities of Quetiapine.
Quinethazone
Salbutamol may increase the hypokalemic activities of Quinethazone.
Quinidine
Salbutamol may increase the QTc-prolonging activities of Quinidine.
Quinine
Salbutamol may increase the QTc-prolonging activities of Quinine.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Salbutamol.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Salbutamol.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Salbutamol.
Saquinavir
Salbutamol may increase the QTc-prolonging activities of Saquinavir.
Saquinavir Mesylate
Salbutamol may increase the QTc-prolonging activities of Saquinavir.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Salbutamol.
Silodosin
Silodosin may decrease the vasoconstricting activities of Salbutamol.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Salbutamol.
Sotalol
Salbutamol may increase the QTc-prolonging activities of Sotalol.
Spironolactone
Spironolactone may decrease the vasoconstricting activities of Salbutamol.
Sulfisoxazole
Salbutamol may increase the QTc-prolonging activities of Sulfisoxazole.
Tamsulosin
Tamsulosin may decrease the vasoconstricting activities of Salbutamol.
Telavancin
Salbutamol may increase the QTc-prolonging activities of Telavancin.
Telithromycin
Salbutamol may increase the QTc-prolonging activities of Telithromycin.
Terazosin
Terazosin may decrease the vasoconstricting activities of Salbutamol.
Tetrabenazine
Salbutamol may increase the QTc-prolonging activities of Tetrabenazine.
Thioridazine
Salbutamol may increase the QTc-prolonging activities of Thioridazine.
Tianeptine
The risk or severity of adverse effects can be increased when Tianeptine is combined with Salbutamol.
Timolol
Timolol may decrease the bronchodilatory activities of Salbutamol.
Timolol Anhydrous
Timolol may decrease the bronchodilatory activities of Salbutamol.
Toloxatone
The risk or severity of adverse effects can be increased when Toloxatone is combined with Salbutamol.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Salbutamol.
Toremifene
Salbutamol may increase the QTc-prolonging activities of Toremifene.
Torsemide
Salbutamol may increase the hypokalemic activities of Torasemide.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salbutamol.
Trichlormethiazide
Salbutamol may increase the hypokalemic activities of Trichlormethiazide.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Salbutamol.
Urapidil
Urapidil may decrease the vasoconstricting activities of Salbutamol.
Vandetanib
Salbutamol may increase the QTc-prolonging activities of Vandetanib.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Salbutamol.
Venlafaxine
Venlafaxine may increase the tachycardic activities of Salbutamol.
Ziprasidone
Salbutamol may increase the QTc-prolonging activities of Ziprasidone.
Zuclopenthixol
Salbutamol may increase the QTc-prolonging activities of Zuclopenthixol.
